ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC) Options
In Phase C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will receive ABBV-744 and ruxolitinib. Members will acquire treatment until eventually disorder progression or even the contributors are unable to tolerate the study drugs.- Participant consumed grapefruit or grapefruit products within three days ahead of the ma